ML19234A289
| ML19234A289 | |
| Person / Time | |
|---|---|
| Issue date: | 09/10/2019 |
| From: | John Lubinski NRC/NMSS/DMSST |
| To: | Palestro C Hofstra University/Northwell Health |
| Jamerson, Kellee | |
| References | |
| Download: ML19234A289 (3) | |
Text
C. Palestro 1
September 10, 2019 Christopher J. Palestro, M.D.
ACMUI Chairman Chief, Division of Nuclear Medicine and Molecular Imaging Hofstra University/Northwell Health 270-05 76th Avenue New Hyde Park, NY 11040
SUBJECT:
ADVISORY COMMITTEE ON THE MEDICAL USES OF ISOTOPES CHAIRMAN AND VICE CHAIRMAN APPOINTMENT
Dear Dr. Palestro:
I would like to thank you for your eight years of dedicated service as the Nuclear Medicine Physician representative on the Advisory Committee on the Medical Uses of Isotopes (ACMUI) and for your leadership while serving as the ACMUI Chairman.
The U.S. Nuclear Regulatory Commission (NRC) staff has benefitted from your expertise on several regulatory issues associated with the medical use of byproduct material through your participation on several ACMUI subcommittees that addressed a wide variety of topics, including the Licensing of Radium-223 Dichloride; the Abnormal Occurrence Criteria for Medical Uses; the NRC Medical Uses Policy Statement; the ACMUI Bylaws; the Hormesis/Linear-No-Threshold Petitions; Decommissioning Funding for Germanium-68 Generators; the Yttrium-90 Microsphere Brachytherapy Sources and Devices TheraSpheres and SIR-Spheres Licensing Guidance; and the Nursing Mother Guidelines for the Medical Administration of Radionuclides. You also served in a leadership role by chairing three subcommittees that involved complicated and very relevant medical policy issues, namely, the NorthStar Molybdenum-99/Technetium-99m Generator (RadioGenix') Licensing Guidance Subcommittee; the Training and Experience Requirements for Authorized Users of Alpha and Beta Emitters under 10 CFR 35.390 Subcommittee; and the Training and Experience Requirements for all Modalities Subcommittee.
During your term with the ACMUI, you also gave several briefings during public ACMUI Commission meetings that have resulted in the NRC staff and the Commission gaining a better understanding of the Committees views on topics such as training and experience requirements for authorized users and impacts to the medical community on the availability of molybdenum-99 production.
I would also like to inform you that I have selected Dr. Darlene Metter as the next ACMUI Chairman and Dr. Arthur R. Schleipman as the next ACMUI Vice Chairman.
Dr. Metter has served on the ACMUI since March 2016. She has served on six subcommittees, three of which she chaired. Dr. Metters leadership experience includes a gubernatorial
C. Palestro 2
appointment to the Texas Radiation Advisory Board and chair of the Radioactive Drug Research Committee at the University of Texas Health Science Center at San Antonio. She has proactively engaged with the American College of Radiology and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to enhance communications between the NRC and the medical community.
Dr. Schleipman has served on the ACMUI since September 2018. While fairly new to the ACMUI, Dr. Schleipman has been a significant contributor during the Committees deliberations on numerous topics. He has served on five subcommittees, one of which he chaired.
Dr. Schleipmans leadership experience in the medical setting spans both technical and administrator responsibilities, including an appointed position as Associate Chair of the Institutional Review Board within the Human Research Office at Partners HealthCare. He is also an active member of SNMMI.
Based on these experiences, I have concluded that these two individuals are most suitable for the ACMUI Chairman and Vice Chairman position. Dr. Metter and Dr. Schleipman will assume these roles on September 23, 2019, when your second and final term has concluded.
If you have any questions, please contact Kellee Jamerson, ACMUI Coordinator, at Kellee.Jamerson@nrc.gov or (301) 415-7408. Thank you again for your dedicated service and leadership of the ACMUI.
Sincerely,
/RA/
John W. Lubinski, Director Office of Nuclear Material Safety and Safeguards cc: D. Metter
- via email OFFICE MSST MSST MSST TechEd NMSS NAME KJamerson CEinberg AKock LMoorin JLubinski DATE 08/22/2019 08/22/2019 9/6/19 9/10/19 9/10/19